

# Antonio Vitale

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9321506/antonio-vitale-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

111  
papers

2,524  
citations

30  
h-index

43  
g-index

118  
ext. papers

3,041  
ext. citations

3.8  
avg, IF

4.7  
L-index

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 111 | Anakinra treatment in drug-resistant Behçet's disease: a case series. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 1293-301   | 3.9  | 92        |
| 110 | Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. <i>Clinical Research in Cardiology</i> , <b>2012</b> , 101, 525-31             | 6.1  | 81        |
| 109 | Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 191-197  | 3.9  | 74        |
| 108 | Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 1281-6   | 3.9  | 72        |
| 107 | Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 1220-9  | 13.6 | 69        |
| 106 | Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 194864  | 4.3  | 64        |
| 105 | Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. <i>International Journal of Rheumatology</i> , <b>2013</b> , 2013, 513782  | 2    | 63        |
| 104 | The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 43, 818-23               | 5.3  | 62        |
| 103 | Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series. <i>Dermatology</i> , <b>2014</b> , 228, 211-4  | 4.4  | 61        |
| 102 | Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. <i>Mediators of Inflammation</i> , <b>2013</b> , 2013, 939847   | 4.3  | 60        |
| 101 | Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 183-189  | 3.9  | 59        |
| 100 | A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 380 | 5.6  | 57        |
| 99  | Diagnosis and classification of relapsing polychondritis. <i>Journal of Autoimmunity</i> , <b>2014</b> , 48-49, 53-9  | 15.5 | 55        |
| 98  | Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2233-2240                                  | 3.9  | 52        |
| 97  | Key Facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. <i>Clinical Rheumatology</i> , <b>2014</b> , 33, 1197-207   | 3.9  | 49        |
| 96  | A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 463-468                                       | 3.9  | 48        |
| 95  | The hereditary autoinflammatory disorders uncovered. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 892-900  | 13.6 | 47        |

|    |   |      |    |
|----|---|------|----|
| 94 | Adalimumab effectiveness in Behçet disease: short and long-term data from a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 451-455   | 3.9  | 45 |
| 93 | Diagnosis of PFAPA syndrome applied to a cohort of 17 adults with unexplained recurrent fevers. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, 269-71  | 2.2  | 44 |
| 92 | Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,  | 6.3  | 41 |
| 91 | The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature. <i>Autoimmunity Reviews</i> , <b>2012</b> , 12, 10-3  | 13.6 | 38 |
| 90 | The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 17-28  | 3.9  | 36 |
| 89 | Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet Syndrome: A Retrospective Study of Seventy Patients With Vascular Involvement. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 1500-1507  | 9.5  | 36 |
| 88 | A case of resistant adult-onset periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, 593   | 2.2  | 36 |
| 87 | Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 407-415  | 3.9  | 34 |
| 86 | Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives. <i>Current Rheumatology Reports</i> , <b>2016</b> , 18, 3   | 4.9  | 33 |
| 85 | Clinical and biochemical landmarks in systemic autoinflammatory diseases. <i>Annals of Medicine</i> , <b>2012</b> , 44, 664-73  | 1.5  | 32 |
| 84 | Quality of life impairment in Behçet disease and relationship with disease activity: a prospective study. <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 947-955  | 3.7  | 31 |
| 83 | New therapeutic solutions for Behçet syndrome. <i>Expert Opinion on Investigational Drugs</i> , <b>2016</b> , 25, 827-409   |      | 31 |
| 82 | Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). <i>Rheumatology International</i> , <b>2015</b> , 35, 1943-7  | 3.6  | 30 |
| 81 | Cumulative retention rate of adalimumab in patients with Behçet disease-related uveitis: a four-year follow-up study. <i>British Journal of Ophthalmology</i> , <b>2018</b> , 102, 637-641  | 5.5  | 30 |
| 80 | Rare NLRP12 variants associated with the NLRP12-autoinflammatory disorder phenotype: an Italian case series. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 155-6  | 2.2  | 30 |
| 79 | Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2805-2809  | 3.9  | 28 |
| 78 | Certolizumab Pegol treatment in Behçet disease with different organ involvement: A multicenter retrospective observational study. <i>Modern Rheumatology</i> , <b>2017</b> , 27, 1031-1035  | 3.3  | 27 |
| 77 | Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseasesResponse to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. <i>Expert Opin Biol Ther</i> . 2015;15:1677-1683 <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 1311-2 | 5.4  | 27 |

|    |   |     |    |
|----|---|-----|----|
| 76 | Long-term clinical course of patients carrying the Q703K mutation in the NLRP3 gene: a case series. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, 943-6   | 2.2 | 27 |
| 75 | One year in review 2015: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, 259-71   | 2.2 | 27 |
| 74 | Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1405-1411   | 2.4 | 26 |
| 73 | The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. <i>Ocular Immunology and Inflammation</i> , <b>2020</b> , 28, 298-304  | 2.8 | 26 |
| 72 | Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis. <i>Ocular Immunology and Inflammation</i> , <b>2019</b> , 27, 34-39  | 2.8 | 25 |
| 71 | PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 501-5   | 3.9 | 24 |
| 70 | Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. <i>Journal of Medical Case Reports</i> , <b>2015</b> , 9, 123   | 1.2 | 24 |
| 69 | The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 141-9                  | 2.2 | 24 |
| 68 | Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 2063-2069   | 3.9 | 23 |
| 67 | Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet's Disease. <i>Ocular Immunology and Inflammation</i> , <b>2019</b> , 27, 58-63   | 2.8 | 23 |
| 66 | Untangling the web of systemic autoinflammatory diseases. <i>Mediators of Inflammation</i> , <b>2014</b> , 2014, 9481454  | 1.5 | 22 |
| 65 | Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 63-70  | 3.9 | 22 |
| 64 | Interleukin-1 Inhibition in Behçet's disease. <i>Israel Medical Association Journal</i> , <b>2016</b> , 18, 171-6   | 0.9 | 22 |
| 63 | Canakinumab efficacy in refractory adult-onset PFAPA syndrome. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 1050-1051   | 2.3 | 21 |
| 62 | Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 1817-20  | 3.9 | 20 |
| 61 | Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 1687-1690 | 3.9 | 19 |
| 60 | Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 2631-2638  | 3.9 | 19 |
| 59 | Demographic, clinical and therapeutic findings in a monocentric cohort of adult patients with suspected PFAPA syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 77-81   | 2.2 | 19 |

|    |  |      |    |
|----|--|------|----|
| 58 | Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 680-683  | 2.2  | 19 |
| 57 | Working the endless puzzle of hereditary autoinflammatory disorders. <i>Modern Rheumatology</i> , <b>2014</b> , 24, 381-9  | 3.3  | 18 |
| 56 | Long-Term Retention Rate of Anakinra in Adult Onset Still Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 296  | 5.6  | 17 |
| 55 | Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 807-9  | 3.9  | 17 |
| 54 | Diagnostic Criteria for Adult-Onset Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1018   | 8.4  | 17 |
| 53 | Mucocutaneous Involvement in Behçet Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 451675   | 4.3  | 17 |
| 52 | Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behçet disease. <i>Immunology Letters</i> , <b>2018</b> , 201, 38-44   | 4.1  | 17 |
| 51 | Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders. <i>Israel Medical Association Journal</i> , <b>2015</b> , 17, 93-7   | 0.9  | 17 |
| 50 | One year in review 2016: novelties in the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 357-72  | 2.2  | 17 |
| 49 | Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. <i>Mediators of Inflammation</i> , <b>2019</b> , 2019, 1623847                                   | 4.3  | 16 |
| 48 | Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy. <i>Israel Medical Association Journal</i> , <b>2017</b> , 19, 478-483                                 | 0.9  | 15 |
| 47 | Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 918  | 5.6  | 13 |
| 46 | Serum amyloid-A in Behçet disease. <i>Clinical Rheumatology</i> , <b>2014</b> , 33, 1165-7   | 3.9  | 13 |
| 45 | Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. <i>Mediators of Inflammation</i> , <b>2020</b> , 2020, 8562485 | 4.3  | 13 |
| 44 | Predictors of sustained clinical response in patients with Behçet disease-related uveitis treated with infliximab and adalimumab. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 1715-1720   | 3.9  | 12 |
| 43 | Evolving Frontiers in the Treatment of Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA) Syndrome. <i>Israel Medical Association Journal</i> , <b>2017</b> , 19, 444-447   | 0.9  | 11 |
| 42 | Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma. <i>Internal Medicine Journal</i> , <b>2017</b> , 47, 1086-1088                    | 1.6  | 10 |
| 41 | Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2017</b> , 52, 34-44  | 12.3 | 9  |

|    |   |     |   |
|----|---|-----|---|
| 40 | The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experience from a referral center in Italy. <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 605-611   | 3.7 | 9 |
| 39 | Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease. <i>Mediators of Inflammation</i> , <b>2020</b> , 2020, 8054961  | 4.3 | 8 |
| 38 | Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. <i>Inflammopharmacology</i> , <b>2020</b> , 28, 711-718                             | 5.1 | 7 |
| 37 | Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF- $\alpha$ inhibition: a narrative review. <i>Clinical Rheumatology</i> , <b>2020</b> , 39, 327-337  | 3.9 | 7 |
| 36 | The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1468   | 5.6 | 7 |
| 35 | Hints for Genetic and Clinical Differentiation of Adult-Onset Monogenic Autoinflammatory Diseases. <i>Mediators of Inflammation</i> , <b>2019</b> , 2019, 3293145   | 4.3 | 7 |
| 34 | Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 353  | 2.2 | 7 |
| 33 | Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 93-97 | 2.2 | 7 |
| 32 | Serum immunoglobulin D levels in patients with Behçet's disease according to different clinical manifestations. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 110-115   | 2.2 | 7 |
| 31 | Efficacy of anti-tumour necrosis factor- $\alpha$ monoclonal antibodies in patients with non-infectious anterior uveitis. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 301-305   | 2.2 | 7 |
| 30 | Challenges and new horizons in the periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome. <i>Expert Opinion on Orphan Drugs</i> , <b>2017</b> , 5, 165-171   | 1.1 | 6 |
| 29 | Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2017</b> , 33, 549-555  | 2.6 | 6 |
| 28 | Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 42  | 4.9 | 6 |
| 27 | Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 1031-1039  | 3.7 | 6 |
| 26 | Lights and shadows in autoinflammatory syndromes from the childhood and adulthood perspective. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 565-72  | 3.9 | 6 |
| 25 | Interleukin-1 blockade in neuro-Behçet's disease: a case-based reflection. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 1046-1049   | 2.3 | 6 |
| 24 | Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting with refractory chronic arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S171-2   | 2.2 | 6 |
| 23 | Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. <i>Israel Medical Association Journal</i> , <b>2018</b> , 20, 438-441                         | 9.9 | 6 |

|    |   |     |   |
|----|---|-----|---|
| 22 | Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. <i>Mediators of Inflammation</i> , <b>2020</b> , 2020, 1936960   | 4.3 | 5 |
| 21 | Long-Term Outcomes of Behçet Syndrome-Related Uveitis: A Monocentric Italian Experience. <i>Mediators of Inflammation</i> , <b>2020</b> , 2020, 6872402   | 4.3 | 5 |
| 20 | Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant. <i>International Journal of Rheumatic Diseases</i> , <b>2015</b> , 18, 473-5 | 2.3 | 5 |
| 19 | Effectiveness of SB5, an Adalimumab Biosimilar, in Patients With Noninfectious Uveitis: A Real-Life Monocentric Experience. <i>Asia-Pacific Journal of Ophthalmology</i> , <b>2021</b> , 10, 360-365  | 3.5 | 4 |
| 18 | The eye involvement in monogenic autoinflammatory diseases: literature review and update. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 110, 44-53   | 2.2 | 4 |
| 17 | Auditory involvement in Behçet disease: relationship with demographic, clinical, and therapeutic characteristics. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 445-449  | 3.9 | 3 |
| 16 | Safety of systemic treatments for Behçet syndrome. <i>Expert Opinion on Drug Safety</i> , <b>2020</b> , 19, 1269-1301   | 4.1 | 3 |
| 15 | The joint involvement in adult onset Still disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. <i>Scientific Reports</i> , <b>2021</b> , 11, 12455   | 4.9 | 3 |
| 14 | Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 668173                          | 4.9 | 3 |
| 13 | Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet Disease. <i>Israel Medical Association Journal</i> , <b>2018</b> , 20, 517-521  | 0.9 | 3 |
| 12 | Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis.. <i>Ophthalmology and Therapy</i> , <b>2022</b> , 11, 899   | 5   | 2 |
| 11 | Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis.. <i>Ophthalmology and Therapy</i> , <b>2022</b> , 11, 887   | 5   | 1 |
| 10 | Impact of smoking habit on adult-onset Still disease prognosis, findings from a multicentre observational study. <i>Clinical Rheumatology</i> , <b>2021</b> , 1   | 3.9 | 1 |
| 9  | Clinical profile and evolution of patients with juvenile-onset Behçet syndrome over a 25-year period: insights from the AIDA network. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 2163-2171  | 3.7 | 1 |
| 8  | Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. <i>Rheumatology</i> , <b>2021</b> , 60, 5705-5712   | 3.9 | 1 |
| 7  | Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X211037178                                 | 3.8 | 0 |
| 6  | Development and Implementation of the AIDA International Registry for Patients With Still Disease.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 878797  | 4.9 | 0 |
| 5  | Circulating intercellular adhesion molecule 1 (sICAM-1) in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 104, 13-14  | 2.2 |   |

- 4 Musculoskeletal manifestations in hereditary periodic fever syndromes. *Clinical and Experimental Rheumatology*, **2018**, 36 Suppl 110, 25-31 2.2
- 3 Differential serum levels of interleukin-37 in patients with tumour necrosis factor receptor-associated periodic syndrome (TRAPS). *Clinical and Experimental Rheumatology*, **2019**, 37 Suppl 121, 159-160 2.2
- 2 Efficacy of monoclonal anti-tumour necrosis factor- $\alpha$  antibodies in uveitic macular oedema. *Clinical and Experimental Rheumatology*, **2020**, 38, 621-625 2.2
- 1 Resolution of Schnitzler's syndrome after haematopoietic stem cell transplantation. *Clinical and Experimental Rheumatology*, **2021**, 39, 704 2.2